Sham Digital Program - General health education and interactive quizzes unrelated to anxiety or CBT.Toivoa-001 - A digital Cognitive Behavioral Therapy program combined with NBHWC-certified coaching.
Sham Digital Program - General health education and interactive quizzes unrelated to anxiety or CBT.: General health and wellness information with interactive quizzes. This content is not related to anxiety treatment or CBT techniques.
Toivoa-001 - A digital Cognitive Behavioral Therapy program combined with NBHWC-certified coaching.: A dual mental health treatment consisting of digitally-administered Cognitive Behavioral Therapy combined with National Board Health and Wellness Coach (NBHWC) trained Coaches
Study summary
The purpose of this study is to see if a mobile-delivered mental health program called Toivoa-001, which combines digital cognitive behavioral therapy (CBT) with personal mental health coaching, can effectively reduce anxiety in adults with hearing or mobility disabilities. The study aims to answer whether this dual-intervention digital service is more effective at lowering anxiety symptoms over an 8-week period than a "sham" digital program that is developed to look similar but does not contain active therapeutic content.
The investigators hypothesize that participants who use the Toivoa-001 program will show significantly greater reductions in anxiety compared to those using the sham program, and that these mental health benefits will last through a 12-week follow-up.
Adults within the disability community frequently encounter unique environmental and societal barriers - such as limited physical accessibility, transportation challenges, and workplace inflexibility - that can directly drive or worsen anxiety. By offering a fully remote and accessible mobile tool, this study seeks to determine if a digital health service can deliver scalable, effective anxiety relief tailored to the lived experiences of people with disabilities.
Eligibility
Sex
ALL
Min age
22 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Provision of signed and dated informed consent form
* Presence of self-reported hearing or mobility disability
* Stated willingness to comply with all study procedures and lifestyle considerations and availability for the duration of the study
* Males and females; Age 22 years and above
* Score of 15 or higher on the HAM-A
* Clinical diagnosis of anxiety based on DSM-5 diagnostic criteria
* Willingness to adhere to the Toivoa-001 or sham regimen once per week, including scheduling and weekly meetings with coaches
* Access to necessary resources for participating in a technology-based intervention (e.g., Android phone, iPhone, iPad, internet access)
* Treatment stability (no changes in psychotropic medication or psychotherapy treatment in the 30 days prior to study entry)
* Able to read and speak English fluently
* Resident of the United States and living in the United States for the duration of the trial
Exclusion Criteria:
* Medical diagnosis of psychotic disorder or bipolar disorder
* Participation in another treatment trial at the time of study
* Substance use disorder in the past 12 months (excluding tobacco)
* Suicide attempt in the past year or elevated suicide risk other than passive ideation (i.e., endorsing items reflecting intent, identifying means, suicide planning, or suicide-related preparations)
* Currently pregnant, breastfeeding, or planning to become pregnant during the treatment period
Primary outcome measure(s)
Change in Hamilton Anxiety Rating Scale (HAM-A) from Baseline to Week 8 — From Baseline to end of treatment (8 weeks) The Hamilton Anxiety Rating Scale (HAM-A) is a structured interview using 14 items, each rated from 0 ("not present") to 4 ("severe"). Scores range from 0 to 56. Analyses will use a mixed model for repeated measures (MMRM) in the Intent-to-Treat (ITT) population. The MMRM will model change from Baseline and Weeks 4 and 8 as repeated post-baseline measurements. The model will include fixed effects for treatment group, visit, treatment-by-visit interaction, study site, and Baseline HAM-A total score as a covariate. Within-participant correlation across repeated measurements will be modeled using an appropriate covariance structure. The primary treatment comparison will be the difference between treatment groups in least squares mean change from Baseline to Week 8. Statistical significance for the primary endpoint will be assessed based on the Week 8 treatment contrast from the MMRM. The estimated treatment difference, 95% confidence interval, and two-sided p-value will be reported.
Trial sites (4)
Facility
City
Region
Status
Delaware State University
Dover
Delaware
New Jersey Department of Veterans Health
East Orange
New Jersey
Louis Stokes Cleveland VAMC
Cleveland
Ohio
South Texas Veterans Health Care System
San Antonio
Texas
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.